Subscribe or Manage Preferences

Psoriatic Arthritis

Integrated analysis confirms benefits of 45-mg and 90-mg dosing By Wayne Kuznar San Diego, CA— Ustekinumab (Stelara), a human monoclonal antibody against interleukin (IL)-12 and IL-23, was approved by the US Food and Drug Administration in September 2013, alone or in combination with methotrexate, for the treatment of adults with active psoriatic arthritis. A new integrated analysis of 2 phase 3 clinical trials was presented at the 2013 meeting of the American College of Rheumatology, showing that ustekinumab reduces radiographic progression of joint disease in patients with active psoriatic arthritis.
Stelara a new treatment option for this patient population By Phoebe Starr Madrid, Spain—One-year open-label follow-up of the phase 3 PSUMMIT 2 trial showed that the early improvement that was achieved by week 24 with ustekinumab (Stelara), an interleukin (IL)-2 and IL-23 antagonist, was sustained at week 52 in patients with psoriatic arthritis who had previously received as well as those who had not previously received an anti–tumor necrosis factor (TNF) inhibitor, said lead investigator Christopher T. Ritchlin, MD, MPH, Chief, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, NY, at the 2013 European League Against Rheumatism annual meeting.
A new treatment strategy with a novel IL-17 receptor inhibitor By Phoebe Starr Madrid, Spain—Data from a phase 2 trial for a novel interleukin (IL)-17 inhibitor, called brodalumab, suggest that it may become a new option for the treatment of psoriatic arthritis. Brodalumab was effective in reducing the signs and symptoms of psoriatic arthritis at week 12, and responses were further improved at week 24.
By Phoebe Starr Madrid, Spain—Apremilast, a novel oral inhibitor of phosphodiesterase 4, achieved sustained improvement in the signs and symptoms of psoriatic arthritis, physical function, and skin improvement in the longer-term follow-up of 52 weeks in the PALACE 1 trial, according to results reported for the first time at the 2013 European League Against Rheumatism (EULAR) annual meeting.
Phase 3 data for the PSUMMIT I and PSUMMIT II clinical trials show that ustekinumab (Stelara) is safe and effective in patients with psoriatic arthritis (PsA), and that the improvement persists over 1 year of treatment. By Phoebe Starr
Apremilast, an oral investigational drug, significantly improved the signs and symptoms of psoriatic arthritis (PsA) in patients whose disease failed to respond to previous disease-modifying antirheumatic drugs (DMARDs), including biologic agents, according to the results of the phase 3 clinical trial, PALACE-1. By Phoebe Starr
By Alice Goodman Apremilast, an investigational oral, small-molecule inhibitor of phospho­diesterase (PDE)-4 that mod­ulates an intracellular network of proinflammatory and anti-inflammatory mediators, is currently in phase 3 clinical trials (known as the PALACE trials) for the treatment of patients with psoriatic arthritis.
By Alan Menter, MD Chief of Dermatology, and Director, Dermatology Residency Program, Baylor University Medical Center, Dallas, TX Psoriasis and psoriatic arthritis (PsA) have been intimately linked for only decades. Multi­ple questions remain about the true relationship between psoriasis and PsA.
By David Hawk Berlin, Germany—Results of an analysis presented by Chureen T. Carter, PharmD, MS, Associate Director of Health Economics and Outcomes Research at Janssen Scientific Affairs, Horsham, PA, and colleagues at the 2012 European League Against Rheumatism Congress indicate that during the time period of the introduction of biologic agents for the treatment of psoriatic arthritis, the direct healthcare costs related to psoriatic arthritis management rose from approximately $3500 annually to an annual expenditure exceeding $16,000.
By Neil Canavan Berlin, Germany—A pair of complementary studies presented at the 2012 European League Against Rheuma­tism Congress of patients with psoriatic arthritis who have just started anti–tumor necrosis factor (TNF) therapy illustrate that (1) obesity is a negative predictor of achieving minimal disease activity, and (2) patients with psoriatic arthritis who are able to lose weight by adhering to a hypocaloric, fiber-enriched diet can reverse the negative disease outcomes associated with being overweight.
Page 3 of 4
Results 21 - 30 of 32
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology